AIxCrypto Holdings, Inc.

AIxCrypto Holdings, Inc. is a technology infrastructure company that focuses on the intersection of artificial intelligence and blockchain-based programmable systems. The company develops software platforms and programmable infrastructure to enable the tokenization of real-world assets (RWA) and the deployment of Embodied Artificial Intelligence (EAI) in commercial settings. AIxC aims to be a regulated, programmable infrastructure layer connecting traditional capital markets with on-chain systems and AI-enabled commercial systems. The company believes in two simultaneous structural shifts: the move of asset ownership and transaction finalization to distributed ledger technology, and the growth of AI-enabled physical systems like autonomous vehicles, robotics, and connected systems that need programmable infrastructure. In September 2025, the company completed a $41 million PIPE financing. In November 2025, it rebranded from Qualigen Therapeutics to AIxCrypto Holdings, Inc. Initially, the company operated three business lines: the BesTrade DeAI Agent platform, the C10 digital asset treasury and portfolio management tools, and the RWA Embodied AI (EAI) ecosystem. In February 2026, the company's board decided to focus solely on the RWA + Embodied AI (EAI) ecosystem. As a result, AIxC will discontinue development of the BesTrade platform and the C10 portfolio management tools, as these early-stage proofs of concept did not align with the company's revised focus on enterprise and institutional infrastructure. The company does not expect material impairment charges from this discontinuation beyond what has been previously disclosed. AIxC is also evaluating strategic options for its therapeutics programs, previously under the Qualigen brand, which may include continuing the existing QN-302 trial, licensing the asset, or an outright sale.